NCT01933594View on ClinicalTrials.gov

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 5, 2014

Primary Completion Date

April 16, 2018

Study Completion Date

April 16, 2018

Conditions
HIV Infections
Interventions
DRUG

Romidepsin

RMD administered over 4 hours via an intravenous (IV) catheter.

DRUG

Placebo for Romidepsin

Placebo for RMD administered over 4 hours via an IV catheter.

Trial Locations (10)

14642

University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester

15213

University of Pittsburgh CRS, Pittsburgh

19104

Penn Therapeutics, CRS, Philadelphia

27599

Chapel Hill CRS, Chapel Hill

35294

Alabama CRS, Birmingham

43210

Ohio State University CRS, Columbus

80045

University of Colorado Hospital CRS, Aurora

90035

UCLA CARE Center CRS, Los Angeles

02114

Massachusetts General Hospital CRS (MGH CRS), Boston

98104-9929

University of Washington AIDS CRS, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01933594 - Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load | Biotech Hunter | Biotech Hunter